Biblio Discovery — Demo Discovery Service

528 hasil untuk "Kumar, Shaji"

Menampilkan 1–20 · 0,65 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Stem cell transplantation for multiple myeloma

    Kumar, Shaji

    Curr Opin Oncol · 2009 · Inggris · PubMed Central

    PURPOSE OF REVIEW: Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role…

  2. Artikel Jurnal Teks lengkap

    Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

    Kumar, Shaji

    Hematology Am Soc Hematol Educ Program · 2017 · Inggris · PubMed Central

    Considerable progress has been made in the treatment of multiple myeloma in the past decade with median survival for the disease improving significantly. This has come through a combination of better understanding of the disease biology and coordinated research into new treatment approaches…

  3. Artikel Jurnal Teks lengkap

    Don’t let the genie out of the bottle!

    Kumar, Shaji

    Blood · 2024 · Inggris · PubMed Central

  4. Artikel Jurnal Teks lengkap

    One disease, many faces

    Kumar, Shaji

    Haematologica · 2022 · Inggris · PubMed Central

  5. Artikel Jurnal Teks lengkap

    Timing of treatment of smoldering myeloma: delay until progression

    Kumar, Shaji K.

    Blood Adv · 2018 · Inggris · PubMed Central

    This article has a companion Point by Mateos and González-Calle.

  6. Artikel Jurnal Teks lengkap

    What is the ideal approach—doublet, triplet, or quadruplet(s)?

    Kumar, Shaji K.

    Hematology Am Soc Hematol Educ Program · 2024 · Inggris · PubMed Central

    Significant progress has been made in the treatment of multiple myeloma (MM), with the introduction of several new drugs with different mechanisms of action. The treatment of newly diagnosed MM has evolved dramatically with the development of highly effective combinations that include 1 or more of…

  7. Artikel Jurnal Teks lengkap

    Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma

    Painuly, Utkarsh; Kumar, Shaji

    Clin Med Insights Oncol · 2013 · Inggris · PubMed Central

    Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that…

  8. Artikel Jurnal Teks lengkap

    Post-Transplant Maintenance Treatment Options in Multiple Myeloma

    Karam, Dhauna; Kumar, Shaji

    Oncol Ther · 2021 · Inggris · PubMed Central

    Maintenance therapy post autologous stem cell transplant (ASCT) is commonly employed in myeloma patients to prolong remission, as relapse invariably occurs after ASCT. After initial diagnosis and risk stratification, patients receive initial therapy with a combination of drugs, typically a…

  9. Artikel Jurnal Teks lengkap

    The significance of monoclonal gammopathy of undetermined significance

    Kyle, Robert A.; Kumar, Shaji

    Haematologica · 2009 · Inggris · PubMed Central

    …becomes most important. In this perspective article, Drs. Kyle and Kumar highlight the need for a better understanding of the etiology and biology of MGUS. See related paper on page 1714.

  10. Artikel Jurnal Teks lengkap

    Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016

    Tandon, Nidhi; Kumar, Shaji K.

    Indian J Hematol Blood Transfus · 2017 · Inggris · PubMed Central

    This review discusses the landmark studies in the field of multiple myeloma (MM) which were presented at American society of hematology annual meeting, 2016. There were contrary results from two large phase III trials (one from US and one from Europe) that evaluated the role of additional…

  11. Artikel Jurnal Teks lengkap

    MINIMAL RESIDUAL DISEASE ANALYSIS IN MYELOMA – WHEN, WHY & WHERE

    Yanamandra, Uday; Kumar, Shaji K.

    Leuk Lymphoma · 2017 · Inggris · PubMed Central

    The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the therapeutic decision making. A better definition of MRD will aid in tailoring MM therapy further to address the clonal heterogeneity and genomic instability…

  12. Artikel Jurnal Teks lengkap

    Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies

    Larsen, Jeremy T.; Kumar, Shaji

    Rare Cancers Ther · 2015 · Inggris · PubMed Central

    Multiple myeloma (MM) is a clonal plasma cell disorder defined by bone marrow infiltration and osteolytic bone lesions and is the second most common hematologic malignancy after non-Hodgkin lymphoma. The landscape of MM treatment was transformed at the dawn of the twenty-first century by the…

  13. Artikel Jurnal Teks lengkap

    Multiple Myeloma: Diagnosis and Treatment

    Rajkumar, S. Vincent; Kumar, Shaji

    Mayo Clin Proc · 2016 · Inggris · PubMed Central

    The diagnosis and treatment of multiple myeloma (MM) has changed dramatically in the last decade. The disease definition has been updated to allow highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor…

  14. Artikel Jurnal Teks lengkap

    Daratumumab in untreated newly diagnosed multiple myeloma

    Abdallah, Nadine; Kumar, Shaji K.

    Ther Adv Hematol · 2019 · Inggris · PubMed Central

    The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as…

  15. Artikel Jurnal Teks lengkap

    Multiple myeloma current treatment algorithms

    Rajkumar, S. Vincent; Kumar, Shaji

    Blood Cancer J · 2020 · Inggris · PubMed Central

    The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables including age, performance status, comorbidities…

  16. Artikel Jurnal Teks lengkap

    Immunophenotyping in multiple myeloma and related plasma cell disorders

    Kumar, Shaji; Kimlinger, Teresa; Morice, William

    Best Pract Res Clin Haematol · 2010 · Inggris · PubMed Central

    Plasma cell disorders form a spectrum ranging from the asymptomatic presence of small monoclonal populations of plasma cells to conditions like plasma cell leukemia and multiple myeloma, in which the bone marrow can be replaced by the accumulation of neoplastic plasma cells. Immunophenotyping has…

  17. Artikel Jurnal Teks lengkap

    The evolution of stem-cell transplantation in multiple myeloma

    Mahajan, Sarakshi; Tandon, Nidhi; Kumar, Shaji

    Ther Adv Hematol · 2018 · Inggris · PubMed Central

    Autologous stem-cell transplantation (ASCT) remains an integral part of treatment for previously untreated, and may have value in the treatment of relapsed patients with, multiple myeloma (MM). The addition of novel agents like immunomodulators and proteasome inhibitors as induction therapy before…

  18. Artikel Jurnal Teks lengkap

    Stem-cell transplantation in multiple myeloma: how far have we come?

    Soekojo, Cinnie Y.; Kumar, Shaji K.

    Ther Adv Hematol · 2019 · Inggris · PubMed Central

    High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically been an essential part of multiple myeloma (MM) management since early studies demonstrated its efficacy in relapsed disease, and subsequent phase III trials demonstrated better responses and improved survival…

  19. Artikel Jurnal Teks lengkap

    Extramedullary disease in multiple myeloma

    Bansal, Radhika; Rakshit, Sagar; Kumar, Shaji

    Blood Cancer J · 2021 · Inggris · PubMed Central

    When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The…

  20. Artikel Jurnal Teks lengkap

    Immune-based therapies in the management of multiple myeloma

    Zanwar, Saurabh; Nandakumar, Bharat; Kumar, Shaji

    Blood Cancer J · 2020 · Inggris · PubMed Central

    Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved…